BSX - Medical Devices Provider Boston Scientific Cardiovascular Segment Sees Traction In Q3 Company Adjusts Annual Outlook | Benzinga
Boston Scientific Corp (NYSE: BSX) generated Q3 revenues of $3.53 billion, beating the Wall Street estimate of $3.48 billion.
The sales increased 11.2% on a reported basis, 11.1% on an operational basis, and 10.2% on an organic basis, beating the management of approximately 8.5% - 10.5% (7% - 9% organic).
The company earned an adjusted EPS of $0.50, beating ...